2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159567
    Ferroptosis-IN-11 1266755-01-4
    Ferroptosis-IN-11 (compound 43) is a ferroptosis inhibitor. Ferroptosis-IN-11 can inhibit Erastin (HY-15763) induced ferroptosis in HT-1080 human fibroblasts (EC50=36 nM). Ferroptosis-IN-11 can be used in the study of cardiovascular disease and neurodegeneration.
    Ferroptosis-IN-11
  • HY-159584
    LBG20304
    LBG20304 (compound 2s) is a ligand for the homologous GluK5 receptor (IC50: 432 nM), more than 40-fold selective over the homologous GluK1-3 isoforms. Low doses of LBG20304 (<10 μM) have no agonist or antagonist functional response at heterologous GluK2/5 receptors, and at high doses (>10 μM), it exhibits low agonist activity in neuronal slices (rat).
    LBG20304
  • HY-159624
    KK-92A
    KK-92A, a blood-brain barrier penetrated GABAB positive allosteric modulator (PAM), suppresses alcohol self-administration and cue-induced reinstatement of alcohol seeking in rats.
    KK-92A
  • HY-159731
    OX2R agonist 1 2648347-78-6
    OX2R agonist 1 is an OX2R antagonist with an EC50 of less than 100 nM. OX2R agonist 1 can be used in research related to excessive daytime sleepiness or narcolepsy.
    OX2R agonist 1
  • HY-159742
    GP130 modulator-1 2375779-31-8
    GP130 modulator-1 (compound A33) is a gp130 signaling pathway modulator. GP130 modulator-1 can be used in the study of inflammatory and degenerative disorders.
    GP130 modulator-1
  • HY-159826
    Brexanolone caprilcerbate 2681264-65-1
    Brexanolone caprilcerbate is a potent GABAA receptor positive allosteric modulator.
    Brexanolone caprilcerbate
  • HY-159829
    Direclidine 1803346-98-6
    Direclidine is a muscarinic M4 receptor positive allosteric modulator.
    Direclidine
  • HY-159832
    Relicpixant 2445366-94-7
    Relicpixant is a potent purinoreceptor (P2X) antagonist.
    Relicpixant
  • HY-159835
    Oveporexton 2460722-04-5
    Oveporexton is an orexin type 2 receptor (OX2R) agonist.
    Oveporexton
  • HY-159836
    Nivegacetor 2443487-67-8
    Nivegacetor is a potent γ-secretase modulator.
    Nivegacetor
  • HY-159837
    Nispomeben 1443133-41-2
    Nispomeben is a potent non-opioid pain relief drug.
    Nispomeben
  • HY-159880
    AChE/BChE-IN-24 3053509-06-8
    AChE/BChE-IN-24 (compound 5k) is a neuroprotective agent through cholinesterase inhibition. AChE/BChE-IN-24 inhibits AChE and BChE with IC50 values of 16.38 μM and 10.44 μM, respectively.
    AChE/BChE-IN-24
  • HY-159888
    SON38 3034673-37-2
    SON38 is a copper chelator capable of chelating divalent copper. SON38 can inhibit the activity of cholinesterases and has potential applications in Alzheimer's disease research.
    SON38
  • HY-159898
    AChE/BChE-IN-23
    AChE/BChE-IN-23 (Compound 6e) is an AChE/BChE inhibitor (IC50: 0.91 μM, 1.19 μM and 1.01 μM for hAChE, eq BChE and hBChE, respectively). AChE/BChE-IN-23 has antioxidant activity and inhibits Aβ1-42 and Tau protein aggregation. AChE/BChE-IN-23 also inhibits microglial activation by reducing ROS release and mitochondrial injury. AChE/BChE-IN-23 suppresses NLRP3 inflammasome and pro-inflammatory cytokines in human microglial cells. AChE/BChE-IN-23 also reverses the Scopolamine (HY-N0296)-induced memory impairment in mice model.
    AChE/BChE-IN-23
  • HY-159923
    BPRMU191 2131199-52-3
    BPRMU191 is a μ-opioid receptor (MOR) modulator that converts small-molecule morphinan antagonists into G protein-biased MOR agonists, thereby inducing MOR-dependent activation and analgesic effects. Co-administration of BPRMU191 with morphinan antagonists provides analgesia while reducing side effects such as gastrointestinal dysfunction, antinociceptive tolerance, and dependency-related adverse effects. BPRMU191, in combination with morphinan antagonists, offers a potential strategy for studying severe pain management and G protein-coupled receptor modulation.
    BPRMU191
  • HY-159924
    DBPR116 2131200-75-2
    DBPR116 is a prodrug of BPRMU191 (HY-159923) with blood-brain barrier penetration capability. DBPR116 significantly improves the delivery of centrally targeted drugs. In combination with the antagonist Naltrexone (HY-76711), DBPR116 demonstrated superior safety and analgesic efficacy compared to morphine in various in vivo pharmacological studies, including thermal pain models, cancer pain models, constipation, sedation, psychological dependence, heart rate, and respiratory frequency. As a prodrug strategy for peripheral administration, DBPR116 effectively alleviates pain while reducing adverse effects, showing potential as a safer opioid analgesic.
    DBPR116
  • HY-159928
    Neuroprotective agent 8
    Neuroprotective agent 8 (compound AA-9) is an oral active neuroprotective agent by anti-oxidative stress and anti-inflammation. Neuroprotective agent 8 activates PGC-1α and inhibits NLRP3 in the rat MCAO ischemic stroke model.
    Neuroprotective agent 8
  • HY-159931
    HW161023 2920698-73-1
    HW161023 (compound 5) is an orally active AP2-associated protein kinase 1 (AAK1) inhibitor with IC50 values of 5.4 nM and 11.9 μM aganist of AAK1and hERG, respectively. HW161023 inhibits the pain in chronic constriction injury of the sciatic nerve rat model.
    HW161023
  • HY-159941
    tau-0N4R-IN-1 2200453-71-8
    tau-0N4R-IN-1 (Compound 6T) is an BBB-penetrable inhibitor of tau 0N4R oligomerization. tau-0N4R-IN-1 effectively inhibits the fibrosis of tau 0N4R, 2N3R, and 2N4R, exhibits an anti-seeding effect on tau in vitro, reduces the oligomerization of α-syn dose-dependently, and prevents formation of α-syn inclusions. tau-0N4R-IN-1 is stable in mouse microsomes and reduces Aβ plaques in brain tissues from AD patients. tau-0N4R-IN-1 has good pharmacokinetic properties in mice.
    tau-0N4R-IN-1
  • HY-159942
    5-HT7R antagonist 3 1887043-58-4
    5-HT7R antagonist 3 (Compound 6.4) is a selective 5-HT7R antagonist (Ki: 8 nM), with Ki of 511 nM (D2), 8930 nM (5-HT1A) and 5786 nM (5-HT2A), respectively. 5-HT7R antagonist 3 possesses antidepressant and anxiolytic effects in mice.
    5-HT7R antagonist 3
Cat. No. Product Name / Synonyms Application Reactivity